Selectively Targeting FLT3-ITD Mutants over FLT3-wt by a Novel Inhibitor for Acute Myeloid Leukemia
Aoli Wang,Chen Hu,Cheng Chen,Xiaofei Liang,Beilei Wang,Fengming Zou,Kailin Yu,Feng Li,Qingwang Liu,Ziping Qi,Junjie Wang,Wenliang Wang,Li Wang,Ellen L. Weisberg,Wenchao Wang,Lili Li,Jian Ge,Ruixiang Xia,Jing Liu,Qingsong Liu
DOI: https://doi.org/10.3324/haematol.2019.244186
2021-01-01
Haematologica
Abstract:Wild-type FLT3 (FLT3-wt) kinase is expressed in immature hematopoietic cells, placenta, gonads, and brain. It plays important roles in the differentiation and survival of hematopoietic stem cells in bone marrow. In a normal hematopoietic environment, FLT3 is predominantly expressed in CD34 positive cells and integrally involved in early hematopoiesis, reconstitution of multilineage myeloid precursors, and dendritic cell maturation. In acute myeloid leukemia (AML), the internal tandem duplications in the juxtamembrane domain of FLT3 kinase (FLT3-ITD), which displays heterogeneity in amino acid sequences in different patients, is the most prevalent mutation of FLT3 kinase and observed in approximately 30-40% of patients. A number of FLT3 kinase inhibitors have been investigated in clinical trials, such as gilteritinib, crenolanib, quizartinib and midostaurin, etc. However, most of the current FLT3 kinase inhibitors cannot distinguish the structurally similar cKIT kinase and FLT3-wt kinase, which might lead to myelosuppression toxicity. Here, we report the discovery of a novel FLT3-ITD mutant selective inhibitor, CHMFL-FLT3-362 (abbreviated as compound 362), which achieves high selectivity over both FLT3-wt and cKIT kinases. It also displays impressive in vitro and in vivo efficacies against the preclinical models of FLT3ITD AML. We first examined the activities of compound 362 against FLT3-ITD and FLT3-wt using the Z’-LYTE (Invitrogen) biochemical assay with purified FLT3 wt/ITD mutant proteins. The data showed that compound 362 (see Figure 1A for chemical structure) achieved over 30-fold selectivity between FLT3-ITD and FLT3-wt (Figure 1B). Kinetic study of the binding mode revealed that compound 362 was an ATP competitive inhibitor (Figure 1C). We then tested the anti-proliferative effects of compound 362 with a panel of engineered BaF3 cells which were transformed with different FLT3 wt/ITD mutants (Figure 1D and Online Supplementary Table S1). Interestingly, the compound displayed potent inhibitory activity against all ITD mutants with different ITD lengths ranging from 6 to 33 amino acids and achieved 7~30-fold selectivity over FLT3-wt. However, it was much less potent against drug resistant mutants of FLT3-ITD including FLT3-ITD-G697R/D835(del/I/V) /Y824(R/H), and primary gain-of-function mutations including FLT3-D835V/H/N/Y and FLT3-K663Q. All these data suggested that compound 362 was a FLT3ITD mutant selective inhibitor. As expected, this selectivity was recapitulated in leukemia cell lines evidenced by the selective inhibition against FLT3-ITD-dependent AML cells (MV4-11, MOLM-13, and MOLM-14) versus FLT3 wt-expressing cells (U937, CMK, OCI-AML-2, and HL-60) (Figure 1D and Online Supplementary Table S1). To further show the kinome-wide selectivity of compound 362, we examined it with the DiscoverX’s KINOMEscan technology at the concentration of 1 mM. The results demonstrated that compound 362 exhibited a good selectivity profile (S score 35 = 0.02). Besides FLT3, compound 362 also displayed strong binding against cKIT, CSF1R, FLT1, VEGFR2, PDGFRα and PDGFRβ kinases (Figure 1E and Online Supplementary Table S2). Since the KINOMEscan is a binding-based assay and may not really reflect the actual inhibitory activity of the kinase, we then examined compound 362 against these targets with the Z’-LYTE biochemical assay. The results showed that it potently inhibited CSF1R, moderately inhibited PDGFRα and PDGFRβ, but much less potently inhibited cKIT, VEGFR2 and FLT1. This is not surprising since FLT3, CSF1R, and PDGFR kinases all belong to the type III receptor tyrosine kinase family and their ATP binding pockets are structurally highly similar. In addition, since cKIT kinase is off-target of most FLT3 kinase inhibitors and it is directly correlated with myelosuppression toxicity, we further tested compound 362 in the TEL-cKIT transformed BaF3 cells; the GI50 value was 5.6 mM which indicated a much weaker inhibition to cKIT kinase. This result was further verified in a more physiologically relevant M-07e cell line which overexpresses cKIT wt kinase. Again, compound 362 did not affect the phosphorylation of cKIT kinase in this cell line up to 1 mM (Online Supplementary Figure S1). We then investigated the effects of compound 362 on the signaling pathways mediated by FLT3 kinase. The results displayed that the FLT3 autophosphorylation in FLT3-ITD-dependent cell lines (MV4-11, MOLM-13, and MOLM-14) were significantly decreased and the phosphorylation of downstream signaling mediators including STAT5, AKT, and ERK were almost completely inhibited between 0.1 and 0.3 mM (Figure 2A). However, in FLT3-wt-expressing cell lines (OCI-AML-3, NOMO-1), FLT3 autophosphorylation and downstream signaling were not affected up to 3 mM of compound 362, while midostaurin could potently inhibit the FLT3 auto-phosphorylation (Online Supplementary Figure S2). These data further confirmed the selectivity of compound 362 between FLT3-ITD mutants and FLT3-wt. We next evaluated the apoptosis-related proteins in FLT3-ITD cell lines upon compound 362 treatment. Dose-dependent increase of the expression of cleaved caspase-3 and cleaved PARP were observed in these cell lines, which indicated apoptotic cell death (Figure 2B). In addition, dose-dependent cell cycle arrest was observed in FLT3-ITD positive cell lines but not FLT3wt cell lines (Online Supplementary Figures S3 and S4). Furthermore, compound 362 exhibited remarkable antiproliferative effects against FLT3-ITD positive AML patient primary cells but not FLT3-wt primary cells or peripheral blood mononuclear cells (PBMC) (Figure 2C and Online Supplementary Tables S3 and S4). Dosedependent inhibition of the phosphorylation of FLT3 and downstream signaling mediators STAT5, ERK and AKT in these primary cells confirmed the on-target inhibition effects of compound 362 (Figure 2C). We next evaluated the pharmacokinetics properties of compound 362 in rats, mice, and Beagle dogs following intravenous (1 mg/kg) and oral (5-10 mg/kg) administration (Online Supplementary Table S5). The data revealed a good drug-like PK profile including acceptable bioavailability (> 60%), suitable half-life (T1/2 = 1-4 hours [h]), and good Cmax (>3,000 ng/mL). We then used the zebrafish model to examine the safety of compound 362 by testing the effects at 72 h post fertilization (hpf) of embryos. The tail curvature caused by compound 362 was much less than that caused by midostaurin at 1 mM (Online Supplementary Figure S5), indicating a relatively lower toxicity of compound 362. In order to examine the myelosuppression effects, we further examined the effect of compound 362 on WT granulopoiesis using myeloperoxidase (mpx)+ positive cell numbers as a readout of cKIT-related myelopoiesis/myelosuppression. As expected, compound 362 showed no apparent difference of cell num-